Lataa...
lloprost delivered via the BREELIB(TM) nebulizer: a review of the clinical evidence for efficacy and safety
Inhaled iloprost is a well-established medication to treat pulmonary arterial hypertension (PAH), a serious and potentially fatal disease of the pulmonary resistance vessels. The therapeutic administration of iloprost requires six to nine inhalations per day, due to the short biological half-life of...
Tallennettuna:
| Julkaisussa: | Ther Adv Respir Dis |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
SAGE Publications
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6421612/ https://ncbi.nlm.nih.gov/pubmed/30874487 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466619835497 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|